Illustration of the Johnson & Johnson coronavirus vaccine
Dado Ruvic | Reuters
Johnson & Johnson On Tuesday, fourth quarter earnings and sales were reported that exceeded Wall Street expectations. The company also said it would “soon” release important details about its coronavirus vaccine.
According to Refinitiv’s average estimates, J&J has fared compared to Wall Street expectations as follows:
- Adjusted earnings per share: $ 1.86 per share versus $ 1.82 expected.
- Revenue: $ 22.48 billion versus $ 21.67 billion expected.
“I am incredibly proud of our Johnson & Johnson teams around the world who are committed to serving stakeholder needs,” said Alex Gorsky, CEO of J&J, in a press release. “We are continuing to develop our COVID-19 vaccine candidate and look forward to publishing details from our Phase 3 study soon.”
J & J’s share price remained essentially unchanged in premarket trading after the report.
J & J’s pharmaceuticals business, which is working on a coronavirus vaccine, had sales of $ 12.26 billion, up 16% year over year. The company’s consumer unit, which makes products like Listerine, had sales of $ 3.6 billion, up 1.4% year over year. The medical device unit generated $ 6.58 billion, down 0.7%.
J&J is expected to release data from its Phase 3 study testing the Covid-19 vaccine this week.
US officials and Wall Street analysts are curious; excited the federal approval of J & J’s Vaccine that could happen as early as next month. not how Pfizers and Modernas For approved vaccines that require two doses three to four weeks apart, J&J only requires one dose. This means patients do not have to return for another dose, which simplifies logistics for healthcare providers.
This is a developing story. Please try again.
Source link
This article originally appeared on www.cnbc.com
